Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. CSL Limited
  6. News
  7. Summary
    CSL   AU000000CSL8

CSL LIMITED

(CSL)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CSL : Reaffirms Commitment to Manufacture 50 Million Doses of AstraZeneca Vaccine

10/15/2021 | 03:39am EST


ę MT Newswires 2021
All news about CSL LIMITED
11/23Seqirus Announces U.S. FDA Approval for Multi-Dose Vial Presentation of First-Ever Adju..
CI
11/18Australia shares edge up on financials, healthcare boost
RE
11/15Australia shares end higher on strong Chinese data
RE
11/14Australia shares climb on gold, healthcare boost; banks weigh
RE
11/10Australia shares extend losses for fourth day on U.S. inflation threat
RE
11/08Australia shares slip as heavy losses in banks offset strong miners
RE
11/07Australia shares flat as strong miners temper losses in healthcare
RE
10/31Australia shares rise on tech boost; Westpac drops on profit miss
RE
10/28Australia shares inch lower as healthcare boost offsets subdued financials
RE
10/19CSL : Clinical Trial Milestones, Investments in aQIVc and sa-mRNA Influenza Vaccines and N..
AQ
More news
Analyst Recommendations on CSL LIMITED
More recommendations
Financials (USD)
Sales 2022 10 612 M - -
Net income 2022 2 249 M - -
Net Debt 2022 4 018 M - -
P/E ratio 2022 45,1x
Yield 2022 0,99%
Capitalization 101 B 101 B -
EV / Sales 2022 9,92x
EV / Sales 2023 9,03x
Nbr of Employees 25 000
Free-Float 99,9%
Chart CSL LIMITED
Duration : Period :
CSL Limited Technical Analysis Chart | CSL | AU000000CSL8 | MarketScreener
Technical analysis trends CSL LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 222,24 $
Average target price 231,79 $
Spread / Average Target 4,30%
EPS Revisions
Managers and Directors
Paul Roger Perreault Chief Executive Officer, Executive Director & MD
Joy Carolyn Linton Chief Financial Officer
Brian Anthony McNamee Chairman
Andrew Cuthbertson Chief Scientific Officer & Executive Director
William Mezzanotte Chief Medical Officer, EVP & Head-R&D
Sector and Competitors